CYDY: CytoDyn Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 172.54
Enterprise Value ($M) 183.28
Book Value ($M) -92.98
Book Value / Share -0.08
Price / Book -1.86
NCAV ($M) -93.19
NCAV / Share -0.08
Price / NCAV -1.85

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -0.69
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.30
Current Ratio 0.30

Balance Sheet (mrq) ($M)
Current Assets 20.98
Assets 21.19
Liabilities 114.17
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2025-01-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-10-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-09-30 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 ☐TRANSITION REPORT UNDE
2024-08-15 10-K ;da k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 ☐TRANSITION REPORT UNDER SECTION 13 O

(click for more detail)

Similar Companies
CURLF – Curaleaf Holdings, Inc. CVSI – CV Sciences, Inc.
CYAN – Cyanotech Corporation DBVTF – DBV Technologies S.A.
DMKPQ – DMK Pharmaceuticals Corporation


Financial data and stock pages provided by
Fintel.io